Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2019 08:36 ET | Source: AC Immune SA

AC Immune Announces Election of New Chairman of the Board at Annual General Meeting

LAUSANNE, Switzerland, June 28, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
June 27, 2019 07:00 ET | Source: AC Immune SA

AC Immune to Host Key Opinion Leader Meeting on Treating Alzheimer’s in Down Syndrome

LAUSANNE, Switzerland, June 27, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering precision...
June 20, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Initiation of a Phase 2 Substudy to Increase Understanding of Disease Progression in Familial Alzheimer’s Disease

LAUSANNE, Switzerland, June 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
May 15, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Q1 2019 Financial Results and Business Update

Lausanne, Switzerland, May 15, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision Medicine in...
May 15, 2019 07:00 ET | Source: AC Immune SA

AC Immune Reports Q1 2019 Financial Results and Business Update

LAUSANNE, Switzerland, May 15, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision...
April 01, 2019 07:00 ET | Source: AC Immune SA

AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

Lausanne, Switzerland, April 1, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
April 01, 2019 07:00 ET | Source: AC Immune SA

AC Immune to Present at the H.C. Wainwright Global Life Sciences Conference

LAUSANNE, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
March 29, 2019 02:00 ET | Source: AC Immune SA

AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PDTM Conference

Demonstrated high-affinity binding to human Parkinson's disease-brain derived alpha-synuclein Potentially first diagnostic for detecting and monitoring Parkinson's disease Further reinforces...
March 29, 2019 02:00 ET | Source: AC Immune SA

AC Immune Presents New Data on Alpha-Synuclein PET Tracer at AD/PD™ Conference

Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synucleinPotentially first diagnostic for detecting and monitoring Parkinson’s diseaseFurther reinforces...
March 27, 2019 07:01 ET | Source: AC Immune SA

New Clinical Data on AC Immune's Novel Next Generation Tau PET-Tracer Presented by Licensing Partner, Life Molecular Imaging, at AD/PD(TM) Conference

Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSPNew data further support 18F-PI-2620's potential as a new PET Tracer for...